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General remarks S2
6,7-Dimethoxy-3,4-dihydroisoquinoline 2-oxide (6) S2 9,10-Dimethoxy-2-methyl-1-vinyl-3,6,7,11b-tetrahydro-4H-pyrido[2, 1- 
S4 (1'S,2'S,8a'S)-1',2'-Di-tert-butoxy-7'-oxohexahydrospiro[cyclopropane-1-8'(5'H)indolizine] (anti-12), (1'S,2'S,8a'R)-1',2'-di-tert-butoxy-7'-oxohexahydrospiro[cyclopropane-1-8'(5'H)indolizine] (syn-12), and 1-{1-[(3S,4S)-3,4-di-tert-butoxy-3,4-dihydro-2H-pyrrol-5-yl]cyclopropyl}-1-propanone (13)
A mixture of the nitrone 10 (507 mg, 2.21 mmol) and BCP 2 (0.23 mL, 2.43 mmol) in xylenes 
(1'S,2'S,8a'S)-1',2'-Di-tert-butoxy-7'-methylenehexahydrospiro[cyclopropane-1-8'(5'H)indolizine] (15)
The VCP 15 was prepared starting from the ketone anti-12 (280 mg, 0.9 mmol) following the same procedure used to prepare 14 (3 h instead of 18 h). Chromatography on silica gel (eluent:
EtOAc/MeOH, first 14:1, then 10:1) afforded 15 (215 mg, 78%) as a yellow oil. 
15:
(3a'R,9a'S,9b'S)-2',2'-Dimethyl-8'-methylenehexahydrospiro{cyclopropane-1-9'(6'H)[1',3']dioxolo[4',5'-a]indolizine} (17)
The ( Table 1, 
